189 related articles for article (PubMed ID: 23587424)
41. Synthesis and biological evaluation of new salvinorin A analogues incorporating natural amino acids.
Fichna J; Lewellyn K; Yan F; Roth BL; Zjawiony JK
Bioorg Med Chem Lett; 2011 Jan; 21(1):160-3. PubMed ID: 21115248
[TBL] [Abstract][Full Text] [Related]
42. Synthesis and in vitro pharmacological studies of C(4) modified salvinorin A analogues.
Lee DY; He M; Kondaveti L; Liu-Chen LY; Ma Z; Wang Y; Chen Y; Li JG; Beguin C; Carlezon WA; Cohen B
Bioorg Med Chem Lett; 2005 Oct; 15(19):4169-73. PubMed ID: 16051487
[TBL] [Abstract][Full Text] [Related]
43. Synthesis of salvinorin A analogues as opioid receptor probes.
Tidgewell K; Harding WW; Lozama A; Cobb H; Shah K; Kannan P; Dersch CM; Parrish D; Deschamps JR; Rothman RB; Prisinzano TE
J Nat Prod; 2006 Jun; 69(6):914-8. PubMed ID: 16792410
[TBL] [Abstract][Full Text] [Related]
44. Salvia divinorum and salvinorin A: an update on pharmacology and analytical methodology.
Grundmann O; Phipps SM; Zadezensky I; Butterweck V
Planta Med; 2007 Aug; 73(10):1039-46. PubMed ID: 17628834
[TBL] [Abstract][Full Text] [Related]
45. Lack of effect of sublingual salvinorin A, a naturally occurring kappa opioid, in humans: a placebo-controlled trial.
Mendelson JE; Coyle JR; Lopez JC; Baggott MJ; Flower K; Everhart ET; Munro TA; Galloway GP; Cohen BM
Psychopharmacology (Berl); 2011 Apr; 214(4):933-9. PubMed ID: 21140258
[TBL] [Abstract][Full Text] [Related]
46. Salvinorin A: a novel and highly selective kappa-opioid receptor agonist.
Yan F; Roth BL
Life Sci; 2004 Oct; 75(22):2615-9. PubMed ID: 15369697
[TBL] [Abstract][Full Text] [Related]
47. Ultrapotent effects of salvinorin A, a hallucinogenic compound from Salvia divinorum, on LPS-stimulated murine macrophages and its anti-inflammatory action in vivo.
Aviello G; Borrelli F; Guida F; Romano B; Lewellyn K; De Chiaro M; Luongo L; Zjawiony JK; Maione S; Izzo AA; Capasso R
J Mol Med (Berl); 2011 Sep; 89(9):891-902. PubMed ID: 21499737
[TBL] [Abstract][Full Text] [Related]
48. Salvinorin A: the "magic mint" hallucinogen finds a molecular target in the kappa opioid receptor.
Sheffler DJ; Roth BL
Trends Pharmacol Sci; 2003 Mar; 24(3):107-9. PubMed ID: 12628350
[TBL] [Abstract][Full Text] [Related]
49. A unique binding epitope for salvinorin A, a non-nitrogenous kappa opioid receptor agonist.
Kane BE; Nieto MJ; McCurdy CR; Ferguson DM
FEBS J; 2006 May; 273(9):1966-74. PubMed ID: 16640560
[TBL] [Abstract][Full Text] [Related]
50. Salvinorin A analogs and other κ-opioid receptor compounds as treatments for cocaine abuse.
Kivell BM; Ewald AW; Prisinzano TE
Adv Pharmacol; 2014; 69():481-511. PubMed ID: 24484985
[TBL] [Abstract][Full Text] [Related]
51. Effects of salvinorin A, a kappa-opioid hallucinogen, on a neuroendocrine biomarker assay in nonhuman primates with high kappa-receptor homology to humans.
Butelman ER; Mandau M; Tidgewell K; Prisinzano TE; Yuferov V; Kreek MJ
J Pharmacol Exp Ther; 2007 Jan; 320(1):300-6. PubMed ID: 17060493
[TBL] [Abstract][Full Text] [Related]
52. The hallucinogenic herb Salvia divinorum and its active ingredient salvinorin A reduce inflammation-induced hypermotility in mice.
Capasso R; Borrelli F; Zjawiony J; Kutrzeba L; Aviello G; Sarnelli G; Capasso F; Izzo AA
Neurogastroenterol Motil; 2008 Feb; 20(2):142-8. PubMed ID: 17931335
[TBL] [Abstract][Full Text] [Related]
53. Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects.
MacLean KA; Johnson MW; Reissig CJ; Prisinzano TE; Griffiths RR
Psychopharmacology (Berl); 2013 Mar; 226(2):381-92. PubMed ID: 23135605
[TBL] [Abstract][Full Text] [Related]
54. Synthetic studies of neoclerodane diterpenes from Salvia divinorum: exploration of the 1-position.
Holden KG; Tidgewell K; Marquam A; Rothman RB; Navarro H; Prisinzano TE
Bioorg Med Chem Lett; 2007 Nov; 17(22):6111-5. PubMed ID: 17904842
[TBL] [Abstract][Full Text] [Related]
55. Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligands.
Harding WW; Tidgewell K; Byrd N; Cobb H; Dersch CM; Butelman ER; Rothman RB; Prisinzano TE
J Med Chem; 2005 Jul; 48(15):4765-71. PubMed ID: 16033256
[TBL] [Abstract][Full Text] [Related]
56. The hallucinogenic herb Salvia divinorum and its active ingredient salvinorin A inhibit enteric cholinergic transmission in the guinea-pig ileum.
Capasso R; Borrelli F; Capasso F; Siebert DJ; Stewart DJ; Zjawiony JK; Izzo AA
Neurogastroenterol Motil; 2006 Jan; 18(1):69-75. PubMed ID: 16371085
[TBL] [Abstract][Full Text] [Related]
57. Differential helical orientations among related G protein-coupled receptors provide a novel mechanism for selectivity. Studies with salvinorin A and the kappa-opioid receptor.
Vortherms TA; Mosier PD; Westkaemper RB; Roth BL
J Biol Chem; 2007 Feb; 282(5):3146-56. PubMed ID: 17121830
[TBL] [Abstract][Full Text] [Related]
58. From local to global-fifty years of research on Salvia divinorum.
Casselman I; Nock CJ; Wohlmuth H; Weatherby RP; Heinrich M
J Ethnopharmacol; 2014 Feb; 151(2):768-83. PubMed ID: 24315983
[TBL] [Abstract][Full Text] [Related]
59. Salvinorin A: allosteric interactions at the mu-opioid receptor.
Rothman RB; Murphy DL; Xu H; Godin JA; Dersch CM; Partilla JS; Tidgewell K; Schmidt M; Prisinzano TE
J Pharmacol Exp Ther; 2007 Feb; 320(2):801-10. PubMed ID: 17060492
[TBL] [Abstract][Full Text] [Related]
60. Salvinorin A: from natural product to human therapeutics.
Vortherms TA; Roth BL
Mol Interv; 2006 Oct; 6(5):257-65. PubMed ID: 17035666
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
